Werewolf Therapeutics announced encouraging clinical data from Phase 1/1b and Phase 1b/2 trials of its cancer immunotherapy drugs WTX-124 and WTX-330. WTX-124 showed durable antitumor activity and was safely administered at the recommended Phase 2 dose both alone and with pembrolizumab in patients with advanced solid tumors. WTX-330 was well tolerated and demonstrated antitumor effects in refractory solid tumor patients. These results support further development of both drugs for treating various solid tumors, with ongoing plans for additional clinical trials.
Werewolf Therapeutics’ clinical data for WTX-124 and WTX-330 provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: of 150 priced health-sector US stocks, 121 rose and 18 fell. Notable movers include INO at USD 1.32 (+8.64%), FLNA at USD 0.48 (+5.94%), and LFST at USD 12.99 (-5.66%).
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
